All sites C00-96,D32-33,D42-43,D45-47,D76 613 88.9 3.1 3.6 1.5 3.0
Mouth, pharynx C00-14 11 94.7 1.8 - - 3.5
  Lip C00 2 100.0 - - - -
  Tongue C02 2 100.0 - - - -
  Mouth, other C03-06 4 95.2 - - - 4.8
  Salivary glands C07-08 2 81.8 9.1 - - 9.1
  Pharynx C01,C09-14 1 100.0 - - - -
Digestive organs C15-26 121 80.9 1.6 9.2 2.5 5.8
  Oesophagus C15 4 89.5 - 5.3 - 5.3
  Stomach C16 11 96.4 - 1.8 1.8 -
  Small intestine C17 3 88.2 - 11.8 - -
  Colon C18 45 92.4 - 1.8 1.3 4.5
  Rectum, rectosigmoid C19-20 18 95.5 - - 1.1 3.4
  Anus C21 0 100.0 - - - -
  Liver C22 7 66.7 - 25.0 - 8.3
  Gallbladder, bile ducts C23-24 4 70.0 - 20.0 - 10.0
  Pancreas C25 27 54.8 7.4 24.4 3.7 9.6
  Other digestive organs C26 2 16.7 - 16.7 41.7 25.0
Respiratory organs C30-39 26 73.5 9.8 3.0 4.5 9.1
  Nose, sinuses C30-31 1 100.0 - - - -
  Larynx, epiglottis C32 - - - - - -
  Lung, trachea C33-34 25 73.0 10.3 2.4 4.8 9.5
  Mediastinum, pleura C38 - - - - - -
Bone C40-41 1 75.0 - - - 25.0
Melanoma of the skin C43 23 100.0 - - - -
Skin, non-melanoma C44 41 100.0 - - - -
Mesothelioma C45 1 100.0 - - - -
Autonomic nervous system C47 0 100.0 - - - -
Soft tissues C48-49 5 92.6 3.7 3.7 - -
Breast C50 189 99.2 0.1 0.2 0.2 0.3
Female genital organs C51-58 68 93.3 1.5 3.2 1.2 0.9
  Cervix uteri C53 7 97.2 - - 2.8 -
  Corpus uteri C54 32 98.8 - 1.2 - -
  Uterus, other C55,C58 0 50.0 - 50.0 - -
  Ovary C56 22 88.1 2.8 6.4 0.9 1.8
  Other female genital C51-52,C57 7 82.4 5.9 2.9 5.9 2.9
Urinary organs C64-68 25 87.4 - 7.9 1.6 3.1
  Kidney C64 17 82.1 - 11.9 2.4 3.6
  Bladder and urinary tract2 C65-68 9 97.7 - - - 2.3
Eye C69 1 42.9 - 28.6 14.3 14.3
Brain, central nervous system C70-72,D32-33,D42-43 21 81.7 - 6.7 3.8 7.7
Thyroid gland C73 9 95.6 2.2 - 2.2 -
Other endocrine glands C74-75 0 50.0 - 50.0 - -
Illdefined or unknown C76,C80 14 52.9 14.3 18.6 2.9 11.4
Lymphoid and haematopoietic tissue C81-96,D45-47,D76 54 70.9 19.4 1.5 3.0 5.2
  Hodgkin lymphoma C81 3 100.0 - - - -
  Non-Hodgkin lymphoma C82-86,C96,D76 26 99.2 - - - 0.8
  Malignant immunoproliferative diseases C88 - - - - - -
  Myeloma and other plasma cell tumors C90 9 39.5 37.2 9.3 7.0 7.0
  Leukaemia C91-95 10 43.8 39.6 - 4.2 12.5
  Myelodysplastic syndromes D46 2 25.0 25.0 - 12.5 37.5
  Myeloproliferaitive neoplasms D45,D47 5 25.0 62.5 - 8.3 4.2
Not included above
  Carcinoma in situ of the breast D05 11 100.0 - - - -
  Cervix uteri, non-invasive neoplasms 13 100.0 - - - -
  Borderline tumour of the ovary D39 11 98.2 - - - 1.8
  Basal cell carcinoma of the skin 212 100.0 - - - -
1 The following order of preference for confirmation of the diagnosis is used:
1. Histology (including autopsy, and bone marrow and blood smear examination in leukaemias)
2. Cytology
3. Surgery (including endoscopy), autopsy without histology, X-ray and some specified laboratory examinations
4. Clinical examination only
2 PUNLMP and ca in situ of the uroepithelium are included.